Home/Pipeline/VNX-208

VNX-208

Non-Small Cell Lung Cancer

PreclinicalActive

Key Facts

Indication

Non-Small Cell Lung Cancer

Phase

Preclinical

Status

Active

Company

Vironexis Biotherapeutics

About Vironexis Biotherapeutics

Vironexis Biotherapeutics, founded in 2021, is developing a transformative platform for AAV-delivered T-cell immuno-gene therapy. The company's TransJoin™ platform is designed to create off-the-shelf, single-infusion therapies that engineer a patient's T cells in vivo to target and kill cancer cells, bypassing the need for complex ex vivo cell manufacturing. Its pipeline includes over ten preclinical programs targeting blood cancers, solid tumors, and cancer prevention, with its lead asset, VNX-101 for CD19+ leukemias and lymphomas, having received FDA IND clearance and multiple regulatory designations. The company is led by a founding team with deep expertise in gene therapy development and oncology.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Non-Small Cell Lung Cancer Drugs

Drug	Company	Phase	Status
CM24	Purple Biotech	Phase 2	Active
Pepinemab (VX15/2503)	Vaccinex	Phase 1b/2	Completed
GC-001	Genocury Biotech	Preclinical	Active
Immunomodulator Platform	OmniCyte	Research	Active
VisAcT (18F-AraG) Imaging in NSCLC	CellSight Technologies	Phase 2	Active
AIC100	AffyImmune Therapeutics	Pre-clinical/Planned	Active
Lung (NSCLC) PD-L1	Mindpeak	Commercial	Active
Tiragolumab	Chugai Pharmaceutical	Phase III	Active
SHR-1701	Jiangsu Hengrui Medicine	Phase II/III	Active
Acasunlimab (DuoBody-PD-L1x4-1BB)	Genmab	Phase 2/3	Active
VAC2	Lineage Cell Therapeutics	Phase 1	Active